POTENTIAL ADVANTAGE OF REPAGLINIDE MONOTHERAPY IN GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND SEVERE RENAL...

Area of Science:

• Endocrinology
• Nephrology
• Pharmacology

Background:

• Oral anti-diabetic drugs (OADs) are primary treatments for type 2 diabetes (T2D).
• OAD availability is often limited in patients with renal impairment (RI).

Purpose of the Study:

• To evaluate the efficacy of repaglinide in T2D patients with severe RI (CKD stage 4).
• Repaglinide is primarily metabolized and excreted via non-renal pathways.

Main Methods:

• Open-label, single-arm, interventional study.
• Repaglinide monotherapy was administered.
• Primary endpoint: HbA1c change from baseline to 12 weeks.

Main Results:

• Significant HbA1c reduction from 7.7% to 6.1% (p<0.001) in 9 patients with severe RI.
• Switching from DPP-4 inhibitors to repaglinide also improved HbA1c.
• No hypoglycemic events reported during the 12-week study period.

Conclusions:

• Repaglinide demonstrates efficacy in T2D patients with severe renal impairment.
• Repaglinide is a suitable alternative when DPP-4 inhibitors do not achieve glycemic targets.